Beclomethasone aerosol in chronic asthma (Hebrew)

S. A. Spitzer, M. Topilsky

Research output: Contribution to journalArticlepeer-review


Of 30 patients suffering from chronic perennial asthma, 24 were steroid dependent with an average daily dose of 7.7 mg prednisone. They were treated with beclomethasone diproprionate aerosol, 100 mg four times daily. During a six mth period, in 29 of the 30, a marked improvement in severity and disability scores, reduction in obstructive ventilatory impairment and marked reduction in use of other medications followed. The use of Salbutamol decreased from an average of 8.9 to 2.4 inhalations per day. In 17 patients, the administration of prednisone was stopped within the first mth and in three others, within three mth after starting beclomethasone. Prednisone withdrawal symptoms, manifested by joint pain and weakness, appeared in seven, while in eight allergic rhinitis recurred. Beclomethasone by inhalation proved to be of great value in chronic asthma and in most cases, can replace oral corticosteroids. It does not appear to have any appreciable systemic effect, since signs of adrenal insufficiency appear and extrabronchial allergic manifestations reappear following the cessation of prednisone therapy made possible by administration of beclomethasone.

Original languageEnglish
Pages (from-to)163-166+191
Issue number4
StatePublished - 1975
Externally publishedYes


Dive into the research topics of 'Beclomethasone aerosol in chronic asthma (Hebrew)'. Together they form a unique fingerprint.

Cite this